| EBOS Group Limited (EBO) ORDINARY FULLY PAID |
Health Care |
$3,475 |
NZX Performance Rights Update
|
27 Apr 2026 11:26AM |
$17.240 |
$16.790 |
fallen by
2.61%
|
|
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$286 |
Conclusion of ASIC matter
|
27 Apr 2026 11:22AM |
$1.570 |
$1.515 |
fallen by
3.50%
|
|
SVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Conclusion of ASIC matter announced by Solvar Limited.
- Federal Court of Australia ordered Money3 Loans Pty Ltd to pay a penalty of $1.55 million.
- Penalty relates to contraventions of the National Consumer Credit Act between 2019 and 2021.
- Solvar Limited is a market-leading consumer and commercial finance company in Australia and New Zealand.
- Money3 has improved governance, complaints handling, hardship, and underwriting practices since the period in question.
- Solvar Limited aims to provide finance for underserviced consumers, particularly for used vehicles.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EBOS Group Limited (EBO) ORDINARY FULLY PAID |
Health Care |
$3,475 |
Notification of cessation of securities - EBO
|
27 Apr 2026 11:18AM |
$17.305 |
$16.790 |
fallen by
2.98%
|
|
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,501 |
Weekly Estimated NTA as at 24 April 2026
|
27 Apr 2026 11:03AM |
$6.660 |
$6.880 |
risen by
3.30%
|
|
| Arcadia Minerals Limited (AM7) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$5 |
Tantalum Prices Surge as Strategic Engagement Continues
|
27 Apr 2026 11:01AM |
$0.037 |
$0.040 |
risen by
8.11%
|
|
| Pathkey.AI Ltd (PKY) ORDINARY FULLY PAID |
Information Technology |
$75 |
Pause in Trading
|
27 Apr 2026 10:57AM |
$0.041 |
$0.064 |
risen by
56.10%
|
|
PKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading in the securities of Pathkey.AI Ltd has been temporarily paused.
- Further announcements are pending to explain the trading pause.
- The trading pause is reported by ASX Listings Compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kelsian Group Limited (KLS) ORDINARY FULLY PAID |
Industrials |
$1,169 |
Change of Director's Interest Notice (Grady)
|
27 Apr 2026 10:39AM |
$3.830 |
$4.305 |
risen by
12.40%
|
|
| Sabre Resources Limited (SBR) ORDINARY FULLY PAID |
Materials |
$4 |
Proposed issue of securities - SBR
|
27 Apr 2026 10:38AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
| Sabre Resources Limited (SBR) ORDINARY FULLY PAID |
Materials |
$4 |
Proposed issue of securities - SBR
|
27 Apr 2026 10:38AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
| Kelsian Group Limited (KLS) ORDINARY FULLY PAID |
Industrials |
$1,169 |
Change of Director's Interest Notice (McArthur)
|
27 Apr 2026 10:38AM |
$3.830 |
$4.305 |
risen by
12.40%
|
|
| Sabre Resources Limited (SBR) ORDINARY FULLY PAID |
Materials |
$4 |
Transformational Copper Gold Acquisition and $2M Placement.
|
27 Apr 2026 10:38AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
SBR - Price-sensitive ASX Announcement
Full Release
Key Points
- Sabre Resources to acquire 80% of Brema Resources Pty Ltd.
- Acquisition includes East Tennant Ridge IOCG projects.
- Issuance of milestone shares conditional on resource targets.
- Funding secured until Decision to Mine stage.
- $2 million placement to strengthen financial position.
- Regulatory, shareholder, and third-party approvals needed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvest Technology Group Ltd (HTG) ORDINARY FULLY PAID |
Information Technology |
$17 |
Investor Webinar
|
27 Apr 2026 10:37AM |
$0.012 |
$0.011 |
fallen by
8.33%
|
|
| Anagenics Limited (AN1) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
AN1 - Appendix 4C & Activity Report for Q3 FY2026
|
27 Apr 2026 10:31AM |
$0.006 |
$0.007 |
risen by
16.67%
|
|
AN1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Anagenics Limited experienced operating cash outflows of $0.3 million in Q3 FY2026, totaling $1.0 million for the nine months ending March 2026.
- The negative cash flow was primarily due to resolving outstanding creditor payments, with anticipated improvements in cash flow expected in the second half of FY2026.
- BLC Cosmetics, a subsidiary of Anagenics, has been restructured and is now trading profitably, with plans to expand its product portfolio.
- York Street Brands' Bouf Haircare, developed using Anagenics' proprietary technology, continued strong performance with royalty revenue of $347,000 in Q3 FY2026.
- Anagenics has invoiced $738,000 in royalty revenue for the nine months ending March 2026.
- The company reported a net cash inflow from financing activities amounting to $924,000 for the quarter.
- Anagenics is focused on growing shareholder value through the global distribution and sales of its proprietary and licensed brands.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$5 |
Options Prospectus
|
27 Apr 2026 10:21AM |
$0.042 |
$0.025 |
fallen by
40.48%
|
|
| Raiden Resources Limited (RDN) ORDINARY FULLY PAID |
Materials |
$10 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
27 Apr 2026 10:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
RDN - Price-sensitive ASX Announcement
Full Release
Key Points
- Due diligence on Crixás Gold Tailings Project ongoing.
- Environmental licensing process continues.
- Cash balance at $12.33 million as of 31 March 2026.
- Expenditure on exploration activities totaled $296k.
- No mining, production, or development expenses incurred.
- Appendix 5B reports a cash decrease, primarily due to operating losses.
- Exploration and acquisition efforts supported by current cash balance.
- Consideration of divestment or joint venture opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lake Resources NL (LKE) ORDINARY FULLY PAID |
Materials |
$102 |
Notification of cessation of securities - LKE
|
27 Apr 2026 10:14AM |
$0.100 |
$0.044 |
fallen by
56%
|
|
| Lion Selection Group Limited (LSX) ORDINARY FULLY PAID |
Financials |
$117 |
Lion commits to invest $1.6M in Plutonic
|
27 Apr 2026 10:12AM |
$0.905 |
$0.820 |
fallen by
9.39%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,387 |
Atlas Arteria receives unsolicited Takeover Offer from IFM
|
27 Apr 2026 10:11AM |
$4.330 |
$5.090 |
risen by
17.55%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria received an unsolicited Takeover Offer from IFM.
- The Bidder's Statement from IFM outlines a Takeover Offer to acquire all securities of Atlas Arteria not already owned by IFM.
- The offer price is A$4.75 cash per security, with a provision to increase to A$5.10 per security if IFM's interest reaches 45% or more.
- The offer includes certain 'best and final' statements.
- The Takeover Offer is conditional on third-party consents, approvals, or waivers.
- Atlas Arteria will establish an Independent Board Committee to evaluate the offer.
- Shareholders are advised to take no action until further notice.
- UBS and Flagstaff are appointed as financial advisers, and Mallesons as legal adviser for the Offer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DroneShield Limited (DRO) ORDINARY FULLY PAID |
Industrials |
$2,112 |
Notice of Annual General Meeting/Proxy Form
|
27 Apr 2026 10:08AM |
$3.690 |
$2.285 |
fallen by
38.08%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$94 |
March 2026 Quarterly Activities Report & Appendix 4C
|
27 Apr 2026 10:07AM |
$0.225 |
$0.160 |
fallen by
28.89%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 3 Knee OA Trial milestone achieved with 50% patient dosing.
- Interim analysis results are targeted for approximately August 2026.
- Global expansion of clinical trial sites, including Hong Kong and Moldova.
- Strong cash position with A$11.3 million in cash and equivalents.
- Additional funding from convertible note facilities and placements.
- Research collaboration with the University of London on PPS effects.
- Scientific publications support iPPS treatment efficacy and mechanism.
- Maintained focus on data quality and protocol integrity in the trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$94 |
Proposed issue of securities - PAR
|
27 Apr 2026 10:06AM |
$0.225 |
$0.160 |
fallen by
28.89%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$94 |
Proposed issue of securities - PAR
|
27 Apr 2026 10:06AM |
$0.225 |
$0.160 |
fallen by
28.89%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$94 |
Upsized $14M Placement Extends Runway Post IA
|
27 Apr 2026 10:05AM |
$0.225 |
$0.160 |
fallen by
28.89%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Paradigm Biopharmaceuticals Limited successfully completed a $14.0 million placement.
- The placement was upsized due to strong investor demand from an initial $8.0 million target.
- A Share Purchase Plan (SPP) was launched to raise an additional $2.0 million.
- The capital raising improves the company's balance sheet and provides funding flexibility.
- Pro forma cash post-placement is approximately $45 million, excluding option exercises.
- Funds raised will support the Phase 3 clinical trial PARA_OA_012, NDA activities, and other costs.
- Attaching Options will be issued, allowing potential for additional funding if exercised.
- Paradigm aims for non-dilutive funding opportunities post-interim analysis through partnerships or licensing.
- The Phase 3 trial PARA_OA_012 is for osteoarthritis treatment using pentosan polysulfate sodium (iPPS).
- The interim analysis for Phase 3 trial is expected in Q3 CY2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flynn Gold Limited (FG1) ORDINARY FULLY PAID |
Materials |
$12 |
March 2026 Quarterly Activities Report and Appendix 5B
|
27 Apr 2026 10:03AM |
$0.025 |
$0.019 |
fallen by
24%
|
|
FG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade mineralization at Henty Silver-Lead-Zinc Project.
- Successful re-sampling at Firetower Tungsten-Gold Project.
- Significant tungsten-bismuth anomalies at Warrentinna Project.
- Net cash outflow from operating activities.
- Sale of non-core projects in Western Australia.
- Potential gold processing hub at Golden Ridge.
- Continued exploration activities across Tasmania.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Eden Innovations Ltd (EDE) ORDINARY FULLY PAID |
Energy |
$86 |
Cleansing notice
|
27 Apr 2026 9:57AM |
$0.190 |
$0.140 |
fallen by
26.32%
|
|
Call 1300 880 160
Start a chat
Schedule a call
